Grant: CIHR Fellowship
University of Calgary
$55,000.00
Clarifying and modifying the natural history of vascular cognitive impairment - a Canadian cohort study with a paired pilot clinical trial
FY 2019-20
Summary
Vascular cognitive impairment (VCI) is the second largest contributor to dementia, and commonly results from cerebral small vessel disease (cCVD). It often coexists with Alzheimer's disease. There is an urgent need for therapies to prevent the progression of cSVD and VCI, especially those that can be applied early before cognition is affected. However, VCI can be quite variable in terms of risk factors and outcomes, so if we are to reliably test potential therapies, it is important to clearly identify patients who are likely to show measurable decline versus those with more stable disease. This postdoctoral project aims to identify markers of these individuals-at-risk using data from the COMPASS-ND (Comprehensive Assessment of Neurodegeneration and Dementia) cohort study of the Canadian Consortium on Neurodegeneration in Aging (CCNA). This cross-country cohort will include around 2,310 patients by 2020 with various forms of dementia and mild memory loss or concerns, about 600 of whom would have VCI. These patients have received detailed risk factor and brain scan assessments and will be followed for at least 2 years to start. We will look for markers in the blood and in brain scans that indicate higher risk of worsening VCI in COMPASS-ND patients - especially when compared to cognitively healthy or stable participants in the study. In parallel, we will also study measures of progressive VCI over a shorter time period (90-days) as part of TRIC-VCI (Trial of Remote Ischemic pre-Conditioning in VCI), also being conducted in partnership with the CCNA. This trial, which I have co-designed with my supervisor, will also give us an initial sense of whether markers of VCI can be modified by Remote Ischemic Conditioning, a promising treatment strategy. Therefore, this post-doctoral project will help pave the road towards smarter selection of both patients and outcomes for VCI trials, in addition to piloting a treatment for further study within our Canadian dementia network.
Department
Program
CIHR Fellowship
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
412358
Name
Ganesh Aravind
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Clarifying and modifying the natural history of vascular cognitive impairment - a Canadian cohort study with a paired pilot clinical trial
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$55,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cerebral Small Vessel Disease; Cohort Study; Dementia; Imaging; Markers; Prognosis; Remote Ischemic Preconditioning; Risk Factors; Trial; Vascular Cognitive Impairment
Abstract
Vascular cognitive impairment (VCI) is the second largest contributor to dementia, and commonly results from cerebral small vessel disease (cCVD). It often coexists with Alzheimer's disease. There is an urgent need for therapies to prevent the progression of cSVD and VCI, especially those that can be applied early before cognition is affected. However, VCI can be quite variable in terms of risk factors and outcomes, so if we are to reliably test potential therapies, it is important to clearly identify patients who are likely to show measurable decline versus those with more stable disease. This postdoctoral project aims to identify markers of these individuals-at-risk using data from the COMPASS-ND (Comprehensive Assessment of Neurodegeneration and Dementia) cohort study of the Canadian Consortium on Neurodegeneration in Aging (CCNA). This cross-country cohort will include around 2,310 patients by 2020 with various forms of dementia and mild memory loss or concerns, about 600 of whom would have VCI. These patients have received detailed risk factor and brain scan assessments and will be followed for at least 2 years to start. We will look for markers in the blood and in brain scans that indicate higher risk of worsening VCI in COMPASS-ND patients - especially when compared to cognitively healthy or stable participants in the study. In parallel, we will also study measures of progressive VCI over a shorter time period (90-days) as part of TRIC-VCI (Trial of Remote Ischemic pre-Conditioning in VCI), also being conducted in partnership with the CCNA. This trial, which I have co-designed with my supervisor, will also give us an initial sense of whether markers of VCI can be modified by Remote Ischemic Conditioning, a promising treatment strategy. Therefore, this post-doctoral project will help pave the road towards smarter selection of both patients and outcomes for VCI trials, in addition to piloting a treatment for further study within our Canadian dementia network.
Competitiondate
201910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ganesh, Aravind
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $55,000~ $0~